{
    "guideline_identifier": "PIIS0923753422047858.txt",
    "cancer_focus": {
        "primary_cancer": "Metastatic Non-Small Cell Lung Cancer (mNSCLC)",
        "related_syndrome_or_condition": "Oligometastatic Disease, Brain Metastases, Bone Metastases, Elderly Patients, Poor Performance Status"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IV (metastatic) per AJCC/UICC TNM 8th Edition",
            "risk_group": "PS 0-1, no ICI contraindication",
            "treatment_plans": [
                {
                    "clinical_context": "First-line NSqNSCC regardless of PD-L1",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab + pemetrexed/platinum",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Tested",
                            "testing_guidance": "IHC using 22C3/SP263/SP142/28-8/73-10 assays; ≥100 tumor cells required"
                        },
                        {
                            "name": "Histology",
                            "status": "Non-squamous",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "First-line NSqNSCC regardless of PD-L1",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Atezolizumab + bevacizumab/paclitaxel/carboplatin",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Tested",
                            "testing_guidance": "IHC using SP142 assay; ≥100 tumor cells required"
                        },
                        {
                            "name": "Histology",
                            "status": "Non-squamous",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "First-line SqCC regardless of PD-L1",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab + carboplatin/nab-paclitaxel",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Tested",
                            "testing_guidance": "IHC using 22C3 assay; ≥100 tumor cells required"
                        },
                        {
                            "name": "Histology",
                            "status": "Squamous",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "PD-L1 ≥50%",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab monotherapy (avoid in never smokers)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "≥50%",
                            "testing_guidance": "IHC using 22C3 assay; report in 10% intervals"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (metastatic) per AJCC/UICC TNM 8th Edition",
            "risk_group": "ICI contraindication",
            "treatment_plans": [
                {
                    "clinical_context": "First-line NSqNSCC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum/pemetrexed → pemetrexed maintenance",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "Histology",
                            "status": "Non-squamous",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "First-line SqCC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum/gemcitabine or taxane",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "Histology",
                            "status": "Squamous",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (metastatic) per AJCC/UICC TNM 8th Edition",
            "risk_group": "Prior ICI treatment",
            "treatment_plans": [
                {
                    "clinical_context": "Second-line NSqNSCC",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Docetaxel ± ramucirumab",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IB"
                },
                {
                    "clinical_context": "Second-line adenocarcinoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Docetaxel + nintedanib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "Histology",
                            "status": "Adenocarcinoma",
                            "testing_guidance": "Pathology confirmation"
                        }
                    ],
                    "esmo_evidence_level": "IIB"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (metastatic) per AJCC/UICC TNM 8th Edition",
            "risk_group": "ECOG PS 2",
            "treatment_plans": [
                {
                    "clinical_context": "Systemic therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum doublets or single-agent chemotherapy",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "ICI therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ICI monotherapy with careful selection",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Tested",
                            "testing_guidance": "IHC using validated assays"
                        }
                    ],
                    "esmo_evidence_level": "IIIB"
                }
            ]
        },
        {
            "staging_criteria": "Oligometastatic disease (≤5 lesions)",
            "risk_group": "Limited metastatic burden",
            "treatment_plans": [
                {
                    "clinical_context": "Radical treatment",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Local consolidative therapy (SABR/surgery) + systemic therapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IIB"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "PD-L1 expression predicts response to immune checkpoint inhibitors. Histology determines chemotherapy/targeted therapy suitability. Molecular testing (EGFR/ALK/ROS1/BRAF/RET/METex14/KRAS G12C/NTRK/HER2) excludes oncogene-addicted disease. STK11/KEAP1 mutations indicate poor prognosis with reduced ICI efficacy."
    }
}